GH

(redirected from growth hormone)
Also found in: Dictionary, Thesaurus, Medical, Legal, Acronyms, Encyclopedia, Wikipedia.

GH

The two-character ISO 3166 country code for GHANA.

GH

1. ISO 3166-1 alpha-2 code for the Republic of Ghana. This is the code used in international transactions to and from Ghanaian bank accounts.

2. ISO 3166-2 geocode for Ghana. This is used as an international standard for shipping to Ghana. Each region of Ghana has its own code with the prefix "GH." For example, the code for Volta is ISO 3166-2:GH-TV.
References in periodicals archive ?
a dose-proportional increase in IGF-I levels was observed following dosing of the three TransCon Growth Hormone dose levels.
Results published in the Lancet medical journal showed an overall three-fold increased risk of dying from cancer for growth hormone patients, while the risk of dying from bowel cancer or Hodgkin's disease was raised 11 times.
A review of the general medical literature demonstrated CTS associated with growth hormone replacement therapy to be extremely rare in children and adolescents.
Human growth hormone is made by the pituitary gland, just under the brain, and is important for normal development and maintenance of our tissues and organs.
The Jockey Club has denied the rumours while saying there is no evidence of the use of growth hormones in racehorses-but, without a test, the claim is weakened.
Human growth hormone is just one therapy deployed by a growing field of medical practitioners who call themselves anti-aging specialists, a legion of latter-day Ponce de Leons.
Prior to the commercial availability of biosynthetic growth hormone (GH), GH was only available as extracts of pituitary gland harvested at autopsy.
When Muresan was growing up, his pituitary gland probably pumped out 10 to 100 times the normal amount of growth hormone.
Exceedingly short children who fail to meet the technical definition of growth hormone deficiency still can benefit from treatment with a synthetic form of the hormone, according to a long-term study conducted at 10 major universities.
This report provides information on the therapeutic development for Growth Hormone Deficiency, complete with latest updates, and special features on late-stage and discontinued projects.
We believe we have established an excellent safety and efficacy profile for our lead program, once-weekly TransCon Growth Hormone, advanced our second clinical candidate, TransCon Treprostinil, into a Phase 1 study, and furthered the science underlying our partnered programs in the fields of diabetes and ophthalmology.
Full browser ?